These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 17699719)

  • 1. Context-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth.
    Hao H; Muniz-Medina VM; Mehta H; Thomas NE; Khazak V; Der CJ; Shields JM
    Mol Cancer Ther; 2007 Aug; 6(8):2220-9. PubMed ID: 17699719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway.
    Robert G; Jullian V; Jacquel A; Ginet C; Dufies M; Torino S; Pottier A; Peyrade F; Tartare-Deckert S; Bourdy G; Deharo E; Auberger P
    Oncotarget; 2012 Dec; 3(12):1688-99. PubMed ID: 23518796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of B-Raf(V600E) cancers by MAPK hyper-activation.
    Atiq R; Hertz R; Eldad S; Smeir E; Bar-Tana J
    Oncotarget; 2016 Apr; 7(14):18694-704. PubMed ID: 26959890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases.
    Sharma A; Tran MA; Liang S; Sharma AK; Amin S; Smith CD; Dong C; Robertson GP
    Cancer Res; 2006 Aug; 66(16):8200-9. PubMed ID: 16912199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
    Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.
    Gopal YN; Deng W; Woodman SE; Komurov K; Ram P; Smith PD; Davies MA
    Cancer Res; 2010 Nov; 70(21):8736-47. PubMed ID: 20959481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
    Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
    Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma.
    Corcoran RB; Rothenberg SM; Hata AN; Faber AC; Piris A; Nazarian RM; Brown RD; Godfrey JT; Winokur D; Walsh J; Mino-Kenudson M; Maheswaran S; Settleman J; Wargo JA; Flaherty KT; Haber DA; Engelman JA
    Sci Transl Med; 2013 Jul; 5(196):196ra98. PubMed ID: 23903755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
    Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
    Hatzivassiliou G; Song K; Yen I; Brandhuber BJ; Anderson DJ; Alvarado R; Ludlam MJ; Stokoe D; Gloor SL; Vigers G; Morales T; Aliagas I; Liu B; Sideris S; Hoeflich KP; Jaiswal BS; Seshagiri S; Koeppen H; Belvin M; Friedman LS; Malek S
    Nature; 2010 Mar; 464(7287):431-5. PubMed ID: 20130576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma.
    Sharma A; Madhunapantula SV; Gowda R; Berg A; Neves RI; Robertson GP
    Am J Pathol; 2013 Apr; 182(4):1151-62. PubMed ID: 23416158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
    Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma.
    Yadav V; Zhang X; Liu J; Estrem S; Li S; Gong XQ; Buchanan S; Henry JR; Starling JJ; Peng SB
    J Biol Chem; 2012 Aug; 287(33):28087-98. PubMed ID: 22730329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RKTG sequesters B-Raf to the Golgi apparatus and inhibits the proliferation and tumorigenicity of human malignant melanoma cells.
    Fan F; Feng L; He J; Wang X; Jiang X; Zhang Y; Wang Z; Chen Y
    Carcinogenesis; 2008 Jun; 29(6):1157-63. PubMed ID: 18515281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.
    Migliardi G; Sassi F; Torti D; Galimi F; Zanella ER; Buscarino M; Ribero D; Muratore A; Massucco P; Pisacane A; Risio M; Capussotti L; Marsoni S; Di Nicolantonio F; Bardelli A; Comoglio PM; Trusolino L; Bertotti A
    Clin Cancer Res; 2012 May; 18(9):2515-25. PubMed ID: 22392911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.
    Whittaker SR; Cowley GS; Wagner S; Luo F; Root DE; Garraway LA
    Mol Cancer Ther; 2015 Dec; 14(12):2700-11. PubMed ID: 26351322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MEK and RAF inhibitors for BRAF-mutated cancers.
    Belden S; Flaherty KT
    Expert Rev Mol Med; 2012 Oct; 14():e17. PubMed ID: 23058743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.
    Lito P; Saborowski A; Yue J; Solomon M; Joseph E; Gadal S; Saborowski M; Kastenhuber E; Fellmann C; Ohara K; Morikami K; Miura T; Lukacs C; Ishii N; Lowe S; Rosen N
    Cancer Cell; 2014 May; 25(5):697-710. PubMed ID: 24746704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation.
    Ikenoue T; Hikiba Y; Kanai F; Aragaki J; Tanaka Y; Imamura J; Imamura T; Ohta M; Ijichi H; Tateishi K; Kawakami T; Matsumura M; Kawabe T; Omata M
    Cancer Res; 2004 May; 64(10):3428-35. PubMed ID: 15150094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.